Diabetes may be independent risk factor for hyperkalaemia [6]

British Medical Journal

Volumn 327, Issue 7418, 2003, Pages 812-

  Jarman, Paul R ^a   Mather, Hugh M ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b EALING HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SPIRONOLACTONE;

CONCENTRATION (PARAMETERS); DISEASE SEVERITY; DRUG EFFECT; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES COMPLICATIONS; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERKALEMIA; RECEPTORS, ANGIOTENSIN; RISK FACTORS; SPIRONOLACTONE;

EID: 0141639660     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Wrenger E, Müller R, Moesenthin M, Welte T, Frölich JC, Neumann KH, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003;327:147-9. (19 July.)
2. Jarman PR, Kehley AM, Mather HM. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J 1995;71:551-2.
3. Odawara M, Asano M, Yamashita K. Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics. Diabet Med 1997;14:169-70.
4. Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J. Hyperkalaemia in the elderly. Clin Chem 1984;30:1409-12.